Direct oral anticoagulants (DOACs) are indicated for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF), which, according to the American College of Cardiology/ American Heart Association/Heart Rhythm Society atrial fibrillation (AF) guidelines, excludes patients with rheumatic mitral stenosis, a mechanical or bioprosthetic heart valve, or mitral valve repair. However, the data regarding use of DOACs in AF patients with other types of valvular heart disease (VHD) are unclear. We aimed to summarize and evaluate the literature regarding the safety and efficacy of DOAC use in NVAF patients with other types of VHD.
| INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia and confers a substantial stroke risk, ranging from <1% to >20% in the absence of anticoagulation. 1 Stroke prevention is a pivotal part of the management of AF patients, with anticoagulation recommended for patients with a CHA 2 DS 2 -VASc score ≥2. 2 Warfarin has been an anticoagulation therapy standard for decades, but now the use of direct oral anticoagulants (DOACs) has become increasingly popular due to enhanced patient convenience secondary to lack of routine therapeutic monitoring and dietary restrictions, rapid onset of action, and predictable pharmacodynamics and pharmacokinetics. Overall, the DOAC agents have been found to reduce the rates of hemorrhagic stroke compared with warfarin, with differences among each agent regarding other measures of efficacy. The major endpoints of the landmark clinical trials are summarized in Table 1 . [3] [4] [5] [6] AF associated with valvular heart disease (VHD) is associated with an even higher thromboembolic risk than AF alone. 1, 7 Compared with patients in normal sinus rhythm, AF increases the risk of stroke 5×, whereas AF coupled with mitral stenosis increases the risk 20 × . 2 AF associated with rheumatic mitral stenosis or a mechanical heart valve carries the highest thromboembolic risk secondary to possible alternative mechanisms of thrombogenesis than those seen with nonvalvular atrial fibrillation (NVAF). 1, 7, 8 Given the differences in thromboembolic risk profiles, it is essential to differentiate NVAF from valvular AF when determining anticoagulation strategies. NVAF is defined by the American College of Cardiology/American Heart Association/Heart Rhythm Society AF guidelines as AF in the absence of rheumatic mitral stenosis, a mechanical or bioprosthetic heart valve, or mitral valve repair. 2 However, definitions of NVAF vary based upon the guideline consulted, yielding a source of confusion for practicing clinicians. 2, 9, 10 Although warfarin is approved for treatment of both NVAF and valvular AF, the DOACs are approved only for patients with NVAF. [11] [12] [13] [14] [15] However, each of the DOAC landmark AF trials varied slightly in their inclusion and exclusion criteria, allowing patients with certain other types of VHD to be enrolled. Growing use of DOACs in clinical practice and confusion over NVAF criteria may cause some practitioners to incorrectly avoid DOACs in AF patients with concurrent VHD. The purpose of this review is to summarize and evaluate the safety and efficacy of DOAC use in NVAF patients with other types of VHD.
| METHODS
Searches of MEDLINE (from 2010 to September 2016), the Cochrane Database (from 2010 to September 2016), and Google Scholar were conducted using the search terms "atrial fibrillation," "valve disease,"
"dabigatran," "rivaroxaban," "apixaban," and "edoxaban." Limits were set for articles written in English with human subjects. Additional data were identified through bibliographic reviews. The exclusion criteria specific to the VHD population are summarized in Table 2 . [16] [17] [18] One consistency noted is that all trials excluded patients with moderate to severe mitral stenosis and mechanical heart valves. However, patients with aortic stenosis, aortic regurgitation, mild mitral stenosis, and mitral regurgitation were enrolled as long as all other inclusion criteria were met. Uniquely, the ARISTOTLE and ENGAGE AF-TIMI 48 trials enrolled patients with bioprosthetic valves. Each subanalyses tested for differences in outcomes based upon overall VHD status (VHD vs no VHD) and each individual DOAC agent compared with warfarin for both the VHD and no-VHD population. The major endpoints of the subanalyses are summarized in Table 3 .
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3 | RESULTS
| Dabigatran
RE-LY was a multicenter, prospective, randomized trial evaluating dabigatran vs warfarin in 18 113 AF patients with a mean CHADS 2 score of 2.1. 3 Patients were randomized to receive dabigatran 110 mg BID, dabigatran 150 mg BID, or dose-adjusted warfarin to maintain a goal international normalized ratio (INR) of 2.0 to 3.0.
Overall, the authors concluded that dabigatran 150 mg was superior to warfarin regarding rates of stroke or systemic embolism (SE) and noninferior regarding rates of major bleeding, whereas dabigatran 110 mg was noninferior for stroke or SE and superior in rates of major bleeding.
Further examining the NVAF population in RE-LY, investigators excluded patients with prosthetic heart valves, hemodynamically significant mitral stenosis, and those with valve disease likely to lead to an intervention before the end of the study period. For subanalysis comparison, 3950 (21.8%) of the total population were deemed to have VHD by investigators, the majority of which were mitral regurgitation. 16 Patients with VHD were older (74 vs 72 years; P = 0.01), more likely to have congestive heart failure (CHF; 39.7% vs 29.8%; P = 0.01) and coronary artery disease (32.5% vs 26.5%; P = 0.01), and had higher mean CHADS 2 scores (2.3 vs 2.1; P < 0.001). 
| Rivaroxaban
The ROCKET AF trial was a multicenter, randomized, 
| Apixaban
The ARISTOTLE trial was a multicenter, randomized, double-blind trial examining apixaban vs warfarin in 18 201 AF patients with a mean CHADS 2 score of 2.1. 5 Patients were randomized to receive either apixaban 5 mg twice daily or dose-adjusted warfarin to maintain a goal INR of 2.0 to 3.0. Apixaban was reduced to 2.5 mg twice daily in patients with ≥2 of the following: age ≥80 years, weight ≤60 kg, and serum creatinine ≥1.5 mg/dL. Overall, the authors concluded that apixaban was superior in prevention of stroke or SE and superior in reduction of rates of major bleeding.
The ARISTOTLE investigators excluded patients with moderate or severe mitral stenosis and patients with other indications for anticoagulation, therefore excluding those with mechanical prosthetic heart valves. For subanalysis comparison, 4808 (26.4%) patients had a history of moderate or severe VHD, the majority being mitral regurgitation. 18 VHD patients were older (71 vs 69 years; P < 0.0001), more likely to have CHF (48.6% vs 30.7%; P < 0.0001), and less likely to have hypertension (85.3% vs 88.2%; P < 0.0001) and diabetes mellitus (22.6% vs 25.8%; P < 0.0001). The mean CHADS 2 score was also higher in patients with VHD (2.2 vs 2.1; P < 0.0001). Outcomes by valve location (mitral vs aortic) were also assessed, and no significant treatment effects were found. A sensitivity analysis was performed that included patients with mild VHD by baseline echocardiography and found that 59.4% of the total ARISTOTLE population had at least mild VHD at baseline. When analyzing this cohort of patients, outcomes were similar to the main analysis for both the primary efficacy (interaction P = 0.90) and safety outcome (interaction P = 0.67). Overall, patients with VHD experienced higher rates of stroke or SE (3.2% VHD vs 2.4% no VHD; HR: 1.34, 95% CI: 1.10-1.62) and death (9.1% VHD vs 6.2% no VHD; HR: 1.48, 95% CI:
1.32-1.67).
A separate subanalysis was published evaluating the outcomes of the 82 patients with a bioprosthetic valve included in the ARISTOTLE trial, 41 patients in each arm. 22 There were no statistical differences between groups other than a higher incidence of hypertension in the warfarin group (98% vs 81%; P = 0.03). No differences were seen regarding the incidence of stroke or SE with the only 2 events occurring in the apixaban group. Rates of major bleeding were also similar (7.9 apixaban vs 5.2 warfarin/100 patient-years; P = 0.61).
| Edoxaban
The ENGAGE AF-TIMI 48 trial was a multicenter, randomized, double-blind trial examining edoxaban vs warfarin in 21 105 AF patients with a mean CHADS 2 score of 2.8. 6 Patients were randomized to receive either edoxaban 60 mg, edoxaban 30 mg, or doseadjusted warfarin to maintain a goal INR of 2.0 to 3.0. Edoxaban doses were halved if patients had a creatinine clearance of 30 to 50 mL/min or were receiving concurrent potent P-glycoprotein inhibitors (verapamil or quinidine). Overall, the authors concluded that both doses of edoxaban were noninferior to warfarin for preventing stroke or SE but exhibited significantly lower rates of major bleeding.
ENGAGE AF-TIMI 48 investigators excluded moderate to severe mitral stenosis and prosthetic heart valves by excluding patients with other indications for anticoagulation, similar to the ARISTOTLE NVAF population. A description or analysis of the VHD population included in ENGAGE AF-TIMI 48 has yet to be published in full at this time.
Of note, ENGAGE AF-TIMI 48 did include patients with preexisting bioprosthetic valves or previous valve surgery, enrolling the largest population of these specific VHD patients in a DOAC trial to date.
| DISCUSSION
Although RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 were designed to assess efficacy in the NVAF population, a number of patients with other types of VHD were included in these trials.
All the trials excluded patients with moderate to severe mitral stenosis and mechanical heart valves but included patients with aortic stenosis, aortic regurgitation, mild mitral stenosis, and mitral regurgitation. In these patients with other types of VHD, subanalyses revealed that DOAC efficacy remains similar to those patients without VHD. Regarding safety, bleeding risk was similar with dabigatran and apixaban, whereas rivaroxaban was associated with a higher bleeding risk in the VHD population. Although the authors did note that the heightened bleeding risk with rivaroxaban may be a chance finding given the post hoc nature of the analysis, use should still be cautioned given the high baseline bleed risk associated with VHD. 17 Although these trials demonstrate promising results, the findings should be interpreted with caution, as these were not prespecified subgroup analyses. It should also be noted that the findings cannot be generalized to all VHD patients, as no patients with moderate to severe mitral stenosis or mechanical heart valves were included in any of the trials. Results from the ROCKET AF subanalysis highlighted that varying types of VHD should not be considered equal, as thromboembolic and/or bleeding risks differed by type of concurrent VHD. 20 Larger studies of VHD patients comparing outcomes based on specific valve location are needed before tailoring anticoagulation therapy to specific VHD etiology. However, it is prudent to examine the VHD etiology and/or location of patients included in each of the clinical trials to avoid use in a patient with a subset of VHD not studied.
Utilization of DOACs in the setting of bioprosthetic valves should be determined on a patient-specific basis based on the limited patient populations studied currently. Although preliminary results with dabigatran are promising, other studies are needed to validate these findings due to the premature termination. 19 In the ARISTOTLE study, outcomes of apixaban with bioprosthetic valves should be viewed as hypothesis generating, given the small number of bioprosthetic valve patients included in the original trial. 22 Results of the ongoing RIVER trial and ENGAGE AF-TIMI 48 VHD subanalysis may also help provide insights regarding DOAC use in AF patients with concurrent bioprosthetic valves for rivaroxaban and edoxaban, respectively. 6, 21 Based upon the current evidence available, NVAF patients with concurrent mitral regurgitation, aortic stenosis, or aortic regurgitation should not be excluded from DOAC therapy based solely upon the presence of VHD. Although mild mitral stenosis patients were included in some clinical trials, concern for increased thrombosis risk with VHD progression may warrant avoidance of DOACs with mild mitral stenosis until further evidence is available. As with all NVAF patients, those with concurrent VHD should still be examined on an individual basis, assessing both thromboembolic and bleed risk, to determine appropriate candidates for DOAC therapy. 
| Review limitations

